IP Library Granted Patent US 9,035,072
Granted Patent B2
US 9,035,072 · App. 13/642,642 · Granted May 19, 2015

Process of producing cycloalkylcarboxamido-indole compounds

Inventors: Daniel T. Belmont (Grafton, MA); Cristian Harrison (Beveryly, MA); Robert Michael Hughes (San Diego, CA); Young Chun Jung (Lexington, MA); Elaine Chungmin Lee (Arlington, MA); Benjamin Joseph Littler (Carlsbad, CA); Peter Jamison Rose (Littleton, MA); David Andrew Siesel (San Diego, CA); Gerald J. Tanoury (Marlborough, MA)
Assignee: Vertex Pharmaceuticals Incorporated
C07D405/12C07D209/12C07D317/46C07D317/60
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,035,072
App. No.
13/642,642
Granted
May 19, 2015
Kind
B2
Abstract

The present invention features processes for preparing compounds, such as (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1), useful for treating CFTR mediated diseases such as cystic fibrosis.

Claims (104)

1. A method for preparing a compound of formula IV:

wherein, independently for each occurrence:

ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;

R 1 and R 2 is independently selected from —R J , —OR J , —N(R J ) 2 , —NO 2 , halogen, —CN, —C 1-4 haloalkyl, —C 1-4 haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —COR J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic;

R 3 is C 1-6 aliphatic optionally substituted with OH, OP, —O—C 1-6 aliphatic, aryl, heteroaryl, —O-aryl, or —O-heteroaryl;

P is a protecting group;

m is an integer from 0 to 3 inclusive;

n is an integer from 1 to 4 inclusive; and

o is an integer from 1 to 3 inclusive;

comprising the steps of:

a) reacting a compound of formula IIIA:

wherein, independently for each occurrence:

R 2 is —R J , —OR J , —N(R J) 2 , —NO 2 , halogen, —CN, —C 1-4 haloalkyl, —C 1-4 haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —COR J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic; and

o is an integer from 0 to 3;

with a halogenating reagent in a first organic solvent to form a compound of formula IIIB:

wherein, independently for each occurrence:

R 2 is —R J , —OR J , —N(R J ) 2 , —NO 2 , halogen, —CN, —C 1-4 haloalkyl, —C 1-4 haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —COR J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic;

o is an integer from 0 to 3; and

Hal is a halide;

b) reacting the compound of formula IIIB in a second organic solvent with a compound of formula IIIC:

wherein:

P is a protecting group;

followed by reduction and treatment with acid to form a compound of formula IIID:

wherein:

R 2 is —R J , —OR J , —N(R J ) 2 , —NO 2 , halogen, —CN, —C 1-4 haloalkyl, —C 1-4 haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —COR J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic;

o is an integer from 0 to 3;

Hal is a halide;

P is a protecting group; and

A ⊖ is an anion;

c) neutralizing a compound of formula IIID in the presence of a base to form a compound of formula IIID-a:

wherein:

R 2 is —R J , —OR J , —N(R J ) 2 , —NO 2 , halogen, —CN, —C 1-4 haloalkyl, —C 1-4 haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic;

o is an integer from 0 to 3;

Hal is a halide; and

P is a protecting group;

d reacting a compound of formula IIID in a third organic solvent with a compound of formula IIIE:

wherein, independently for each occurrence:

R 3 is a C 1-6 aliphatic optionally substituted with OH, OP, —O—C 1-6 aliphatic, aryl, heteroaryl, —O-aryl, or —O-heteroaryl;

in the presence of a catalyst to form a compound of formula III:

wherein, independently for each occurrence:

R 2 is —R J , —OR J , —N(R J ) 2 , —NO 2 , halogen, —CN, —C 1-4 haloalkyl, —C 1-4 haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —COR J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic;

R 3 is C 1-6 aliphatic optionally substituted with OH, OP, —O—C 1-6 aliphatic, aryl, heteroaryl, —O—aryl, or —O-heteroaryl;

P is a protecting group; and

o is an integer from 0 to 3;

e reacting the compound of formula III in a fourth organic solvent with a compound of formula II:

wherein, independently for each occurrence:

ring A is a fused cycloalkyl, heterocycloalkyl, aryl, or heteroaryl ring;

Hal is a halide;

R 1 is independently selected from —R J , —OR J , —N(R J ) 2 , —NO 2 , halogen, —CN, —C 1-4 haloalkyl, —C 1-4 haloalkoxy, —C(O)N(R J ) 2 , —NR J C(O)R J , —SOR J , —SO 2 R J , —SO 2 N(R J ) 2 , —NR J SO 2 R J , —COR J , —CO 2 R J , —NR J SO 2 N(R J ) 2 , —COCOR J ;

R J is hydrogen or C 1-6 aliphatic;

m is an integer from 0 to 3 inclusive; and

n is an integer from 1 to 4 inclusive;

to form the compound of formula IV.

2. The method of claim 1 , wherein in formula IV, ring A is

o is 1 and R 2 is F; P is benzyl; and R 3 is a C 4 aliphatic optionally substituted with OP.

3. The method of claim 1 , wherein in formula IV, R 3 is

4. The method of claim 1 , wherein in formula IV, ring A is

m is 0, n is 1, o is 1 and R 2 is F, P is benzyl, and R 3 is

5. The method of claim 1 , wherein step a) takes place at about 2 ° C. to 42 ° C., the halogenating reagent is N-bromosuccinimide, and the first organic solvent is an aprotic solvent.

6. The method of claim 1 , wherein in step a), the first organic solvent is ethyl acetate.

7. The method of claim 1 , wherein in formula IIIB, o is 1, R 2 is F, and Hal is Br.

8. The method of claim 1 , wherein in formula IIIC, P is benzyl.

9. The method of claim 1 , wherein in step b), the reaction with a compound of formula IIIC takes place at about 60 ° C. to 100 ° C. , the acid is p-toluenesulfonic acid, the reduction is carried out with hydrogen , and the second organic solvent is an aprotic solvent.

10. The method of claim 1 , wherein in step b), the second organic solvent is toluene.

11. The method of claim 1 , wherein in formula IIID, o is 1, R 2 is F, Hal is Br, A ⊖ is Tos − , and P is benzyl.

12. The method of claim 1 , wherein in formula IIIE, R 3 is C(CH 3 ) 2 CH 2 O(benzyl).

13. The method of claim 1 , wherein in step c), the base is an inorganic base.

14. The method of claim 1 , wherein step d takes place at about 60° C. to 100° C., the catalyst is a palladium catalyst , and the third organic solvent is an aprotic solvent.

15. The method of claim 1 , wherein in step d, the third organic solvent is acetonitrile.

16. The method of claim 1 , wherein in step d, the catalyst is selected from palladium(II)acetate, Pd(dppf)Cl 2 , Pd(dba) 2 , tetrakis(triphenylphosphine)palladium(0), (MeCN) 2 PdCl 2 , or tris(dibenzylideneacetone)dipalladium(0).

17. The method of claim 1 , wherein in step d, the catalyst is palladium(II)acetate.

18. The method of claim 1 wherein in step e, ring A is

m is 0, n is 1, and Hal is Cl.

19. The method of claim 1 , wherein in step e, the fourth organic solvent is an aprotic solvent.

20. The method of claim 1 , wherein step e takes place at about −20° C. to 20° C., the compound of formula II is prepared in situ by halogenating the acid precursor and reacted with the compound of formula III without isolation, and the fourth organic solvent is dichloromethane.

21. The method of claim 1 , further comprising removing the two protecting groups from the compound of formula IV to form a compound of formula IVA:

22. The method of claim 21 , wherein the protecting groups are removed by hydrogenation.

23. A method of preparing Compound 1:

comprising the steps of:

a) reacting compound 2:

with a brominating reagent to form a compound 3:

b) reacting compound 3 with compound 4:

followed by reduction to form compound 5:

followed by neutralizing compound 5 with a base to give compound 5a:

c) reacting compound 5a with compound 6:

in the presence of a catalyst to form compound 7:

d) reacting compound 7 with compound 8:

to form compound 9:

and

e) removing the two Bn protecting groups to form Compound 1.

24. The method of claim 23 , wherein:

in step a), the brominating agent is N-bromosuccinimide;

in step b), the reduction is carried out with hydrogen;

in step c), the catalyst is a palladium catalyst;

in step d), compound 8 is made in situ by halogenating the acid precursor without isolation; and

in step e), the Bn protecting groups are removed by hydrogenation.

25. The method of claim 23 , wherein in step c), the catalyst is selected from palladium(II)acetate, Pd(dppf)Cl 2 , Pd(dba) 2 , tetrakis(triphenylphosphine)palladium(0), (MeCN) 2 PdCl 2 , or tris(dibenzylideneacetone)dipalladium(0).

26. The method of claim 23 , wherein in step c), the catalyst is palladium(II)acetate.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2018
From: NUGENT, WILLIAM A.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 045331/0116 →
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
ASSIGNEE CHANGE OF ADDRESS Recorded Feb 17, 2016
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 037841/0274 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2013
From: TANOURY, GERALD J.; HARRISON, CRISTIAN; LITTLER, BENJAMIN JOSEPH; ROSE, PETER JAMISON; HUGHES, ROBERT MICHAEL; JUNG, YOUNG CHUN; SIESEL, DAVID ANDREW; LEE, ELAINE CHUNGMIN; BELMONT, DANIEL T.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 031557/0306 →
Continuity (9)
Provisional Application 61333870 · May 12, 2010
Provisional Application 61329510 · Apr 29, 2010
Provisional Application 61329500 · Apr 29, 2010
Provisional Application 61329493 · Apr 29, 2010
Provisional Application 61327095 · Apr 22, 2010
Provisional Application 61327091 · Apr 22, 2010
Provisional Application 61327057 · Apr 22, 2010
Provisional Application 61327099 · Apr 22, 2010
Related Publication 20130324743A1 · Dec 5, 2013